undamentalytics Newsletter
Sign in

Jaguar Health, Inc. income statement

In fiscal 2025, Jaguar Health, Inc. reported revenue of $11.5m, down 1.5% on the year before, operating income of −$45.9m (a -398.8% margin) and net income of −$53.6m, or −$22.97 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue000446941210121228
Cost of revenue—001343222245
Gross profit—003226210810823
Research and development4674566151819172525
Selling and marketing—1031077996895
General and administrative45611121414171817161918
Operating income−8−12−14−34−31−29−27−41−34−34−31−46−26
Interest expense03113638136001
Income before tax——−15−35−32−39−34−53−48−42−39−54−37
Income tax———−13—0000000—
Net income−9−16−15−22−32−39−34−0−0−0−38−54−52
Diluted EPS−$0.18−$1193730.99−$0.08−$838927.61−$1210073.73−$71134.37−$23685.14−$9286.68−$3808.57−$187.95−$16.34−$22.97—
Diluted shares (average)——————————2m2m—
EBITDA—−12−14−34−30−27−25−39−32−32−29−44−24

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: JAGX vs VRCAJAGX vs SCLXJAGX vs SBFM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Jaguar Health, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Jaguar Health, Inc.